What do transformational shifts mean in terms of ultimate outcomes and ‘value’ of medicines?

Medicines Australia

9 May 2019 - Emerging ‘one-time’ curative therapies create important new options for patients living with difficult and incurable health conditions. While cost remains central to the discussion, it’s important to reset how we view these transformational approaches and consider what these shifts mean in terms of ultimate outcomes and ‘value’.

The Federal Government’s recent approval and funding of Australia’s first cell immunotherapy (Kymriah) should be viewed as a historical step forward in the provision of transformational treatments to Australian patients:

  • Importantly, it marked the arrival of and access to one of the most advanced forms of personalised medicines now being made available.
  • We are now in completely new territory when it comes to the formal assessment and review of these therapies. There is no question that these highly complex technologies are set to change how we review and fund medicines and health technologies moving forward.
  • That future starts now with a review of the National Medicines Policy.

Read Medicines Australia statement

Michael Wonder

Posted by:

Michael Wonder